References
- Mbaeyi SA, Joseph SJ, Blain A, et al. Meningococcal disease among college-aged young adults: 2014–2016. Pediatrics. 2019;143(1):e20182130.
- Marshall GS, Dempsey AF, Srivastava A, et al. US college students are at increased risk for serogroup b meningococcal disease. J Pediatric Infect Dis Soc. 2020;9(2):244–247.
- Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2018 [Internet]. 2018 [cited 2020 Jan 21]. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2018.pdf
- Brooks R, Woods CW, Benjamin DK Jr., et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994–2002. Clin Infect Dis. 2006;43(1):49–54.
- La EM, Talbird SE, Kanadian KV, et al. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease. Hum Vaccin Immunother. 2019;15(4):978–986.
- Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(suppl 2):B3–B9.
- Balmer P, Burman C, Serra L, et al. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118–1130.
- Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–861.
- Ala’aldeen DA, Oldfield NJ, Bidmos FA, et al. Carriage of meningococci by university students, United Kingdom. Emerg Infect Dis. 2011;17(9):1762–1763.
- MacLennan J, Kafatos G, Neal K, et al. Social behavior and meningococcal carriage in British teenagers. Emerg Infect Dis. 2006;12(6):950–957.
- McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak-Oregon, 2015–2016. J Infect Dis. 2017;216(9):1130–1140.
- Breakwell L, Whaley M, Khan UI, et al. Meningococcal carriage among a university student population - United States, 2015. Vaccine. 2018;36(1):29–35.
- Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015–2016. Clin Infect Dis. 2017;64(8):1115–1122.
- Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–327.
- Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608–612.
- Schaffner W, Baker CJ, Bozof L, et al. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: a report by the National Foundation for infectious diseases [Internet]. 2014 [cited 2019 Nov 20]. Available from: https://www.nfid.org/wp-content/uploads/2019/08/meningococcal-b-report.pdf
- Cohn AC, MacNeil JR, Harrison LH, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193.
- Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP) [Internet]. MMWR Recomm Rep; 2013 Mar 22 [cited 2020 Feb 3]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm
- MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–1176.
- Patton ME, Stephens D, Moore K, et al. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine — advisory committee on immunization practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509–513.
- Advisory Committee on Immunization Practices. Advisory Committee on Immunization Practices (ACIP) summary report, June 26–27, 2019 [Internet]. 2019 [cited 2020 Feb 6]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2019-06-508.pdf
- MacNeil JR, Blain AE, Wang X, et al. Current epidemiology and trends in meningococcal disease-United States, 1996–2015. Clin Infect Dis. 2018;66(8):1276–1281.
- Meyer S. Update on the epidemiology of meningococcal disease and guidance for the control of meningococcal disease outbreaks in the U.S. [Internet]. 2017 [cited 2019 Nov 20]. Available from: https://pdfs.semanticscholar.org/presentation/e0b3/aa069eb91e1d831b8c40d4340d21afa4c513.pdf
- Bilukha OO, Rosenstein N, National Center for Infectious Diseases/Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR–7):1–21.
- Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;347:2349–2362.
- Trumenba (MenB-FHbp). Full prescribing information [package insert]. Philadelphia (PA): Pfizer Inc; 2018.
- McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9(2):e00036–18.
- European Medicines Agency. Assessment report: Trumenba [Internet]. 2017 [cited 2019 Nov 20]. Available from: https://www.ema.europa.eu/documents/assessment-report/trumenba-epar-public-assessment-report_en.pdf
- Vesikari T, Ostergaard L, Beeslaar J, et al. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents. Vaccine. 2019;37(12):1710–1719.
- Alderfer J, Srivastava A, Isturiz R, et al. Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence. Hum Vaccin Immunother. 2019;15(9):2205–2216.
- BEXSERO® (Meningococcal Group B Vaccine) [Internet]. 2018 [cited 2019 Nov 1]. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm431447.pdf
- Granoff DM, Pollard AJ, Harrison LH. Meningococcal capsular group B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, et al, editors. Plotkin's Vaccines: Elsevier; 2018. p. 644–662.e646.
- Nolan T, Santolaya ME, de Looze F, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine. 2019;37(9):1209–1218.
- Watson PS, Novy P, Bekkat-Berkani R, et al. Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data. Expert Rev Vaccines. 2019;18(4):343–352.
- Read RC, Dull P, Bai X, et al. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Vaccine. 2017;35(3):427–434.
- Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
- Mbaeyi S Serogroup B meningococcal vaccines booster doses, June 27, 2019 [Internet]. Centers for Disease Control and Prevention; 2019 [cited 2019 Nov 20]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-06/Meningococcal-2-Mbaeyi-508.pdf
- Soeters HM, McNamara LA, Blain AE, et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013–2018. Emerg Infect Dis. 2019;25(3):434–440.
- Donald RG, Hawkins JC, Hao L, et al. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum Vaccin Immunother. 2017;13(2):255–265.
- Vesikari T, Ostergaard L, Diez-Domingo J, et al. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc. 2016;5(2):152–160.
- Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccin Immunother. 2015;11(1):5–13.
- Study B1971012 data on file. New York (NY): Pfizer Inc; 2013.
- Basta N, Wolfson J, Mahmoud A, et al. 4CMenB vaccine immunogenicity up to 1 year after vaccination among university students. Paper presented at: IPNC International Pathogenic Neisseria Conference; 2018 Sep 23–28. Asilomar (CA). Available from: https://custom.cvent.com/A451E6DA02794210AC7A3003BD70ECE3/files/1d230d7bbad84f8484e2c3fa6d92043c.docx
- Lujan E, Winter K, Rovaris J, et al. Serum bactericidal antibody responses of students immunized with a meningococcal serogroup B vaccine in response to an outbreak on a university campus. Clin Infect Dis. 2017;65(7):1112–1119.
- Becker A Meningitis on campus. Reaching students during a meningitis-B outbreak. Paper presented at: 2018 Massachusetts Adult Immunization Conference; 2018 Apr 10; Marlborough (MA). Available from: https://maic.jsi.com/2018-massachusetts-adult-immunization-conference/
- De Maria A Invasive meningococcal serogroup B infection at Smith College: recommendations for the Five College consortium [Internet]. Bureau of Infectious Disease and Laboratory Sciences at the Commonwealth of Massachusetts; 2018 Mar 5 [cited 2019 Nov 20]. Available from: https://www.umass.edu/gateway/sites/default/files/MenBAdvisory_03_05_18_final.pdf
- Five College Consortium. The Campuses [Internet]. 2017 [cited 2019 Nov 20]. Available from: https://www.fivecolleges.edu/consortium/campuses
- Princeton University Emergency Management. Questions and answers - meningitis B vaccines [Internet]. 2017 Jan 5 [cited 2019 Nov 1]. Available from: https://emergency.princeton.edu/MenBFAQ-Vaccine
- University of California Santa Barbara. 2013 Meningococcal serogroup B outbreak UC Santa Barbara [Internet]. 2014 Jun 16–18 [cited 2018 Dec 13]. Available from: https://www.ucop.edu/enterprise-risk-management/_files/risk-summit-2014-ppts/Santa%20Barbara%20Meningitis%20B%20Lessons%20Learned.pdf
- Haubenreiser J, Dunn A Managing meningococcal disease outbreaks in the university setting: Oregon State University and the State of Oregon partnership and response. Paper presented at: National Immunization Conference May 15–17, 2018; [cited 2018 May 16]. Atlanta (Georgia). Available from: http://www.cvent.com/events/48th-national-immunization-conference/agenda-8b963918dc5b4dc3bb548786b087b96f.aspx
- University of Massachusetts Amherst. Frequently asked questions: serogroup B meningococcal disease [Internet]. 2017 [cited 2019 Nov 1]. Available from: http://www.umass.edu/gateway/sites/default/files/Meningitis%20FAQs_Discharge%20Instructions.pdf
- De Maria A Update: invasive Meningococcal Cases at the University of Massachusetts (UMass) Amherst [Internet]. Bureau of Infectious Disease and Laboratory Sciences at the Commonwealth of Massachusetts; 2017 Nov 30 [cited 2019 Nov 20]. Available from: https://www.mass.gov/files/documents/2018/02/27/meningococcaldiseaseadvisory11-30-17.pdf
- Oregon State University. Domestic student immunization requirements [Internet]. 2019 [cited 2019 Nov 20]. Available from: https://studenthealth.oregonstate.edu/general/policies-and-guidelines/immunizations-tb-screening-and-health-history/domestic-student
- Centers for Disease Control and Prevention. Guidance for the evaluation and public health management of suspected outbreaks of meningococcal disease [Internet]. 2019 [cited 2020 Feb 7]. Available from: https://www.cdc.gov/meningococcal/downloads/meningococcal-outbreak-guidance.pdf
- Fisher EA, Poissant T, Luedtke P, et al. Evaluation of mass vaccination clinics in response to a serogroup B meningococcal disease outbreak at a large, public university-Oregon, 2015. J Adolesc Health. 2018;63(2):151–156.
- Capitano B, Dillon K, LeDuc A, et al. Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak. Hum Vaccin Immunother. 2019;15(3):717–724.
- Ritscher AM, Ranum N, Malak JD, et al. Meningococcal serogroup B outbreak response University of Wisconsin-Madison. J Am Coll Health. 2019;67(3):191-196.
- McNamara L Serogroup B meningococcal disease outbreaks and public health responses at universities in the United States. Paper presented at: National Immunization Conference May 15–17, 2018; 2018 May 16. Atlanta (Georgia). Available from: http://www.cvent.com/events/48th-national-immunization-conference/agenda-8b963918dc5b4dc3bb548786b087b96f.aspx
- Ulrich AM, Lammert S, Wolfson J, et al. Validity of self-reported vaccination status and knowledge and attitudes toward MenB vaccine after an outbreak. Paper presented at: The 15th European Meningococcal and Haemophilus Disease Society Congress; 2019 May 27–30. Lisbon (Portugal). Available from: http://emgm2019.pt/en/content/programme/abstract-book/abstract-book.html
- Kempe A, Allison MA, MacNeil JR, et al. Knowledge and attitudes regarding category B ACIP recommendations among primary care providers for children. Acad Pediatr. 2018;18(7):763–768.
- Oliver S Meningococcal vaccine policies among colleges and universities — United States, 2017 [Internet]. 2018 May 16 [cited 2019 Nov 20]. Available from: https://www.acha.org/documents/resources/CDC-ACHA_College_Policies_Meningococcal_Vaccines_2017.pdf
- Oliver SE, Patton ME, Hoban M, et al. Evaluation of meningococcal vaccination policies among colleges and universities - United States, 2017. J Am Coll Health. 2019;1–6.
- Srivastava A, Aldefer J. 2721. US States’ policies for meningococcal vaccination vs. disease epidemiology. Open Forum Infect Dis. 2019;6(Supplement_2):S957–S958.
- Mbaeyi SA, Blain A, Whaley MJ, et al. Epidemiology of meningococcal disease outbreaks in the United States, 2009–2013. Clin Infect Dis. 2019;68(4):580–585.
- Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123–2131.
- McNamara LA, MacNeil JR, Cohn AC, et al. Mass chemoprophylaxis for control of outbreaks of meningococcal disease. Lancet Infect Dis. 2018;18(9):e272–e281.
- California Health Alert Network San Diego. Invasive meningococcal disease outbreak at San Diego State University [Internet]. 2018 [cited 2019 Nov 20]. Available from: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/cahan/communications_documents/9-28-2018%20Final.pdf
- Anonychuk A, Woo G, Vyse A, et al. The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review. Pharmacoeconomics. 2013;31(7):563–576.
- Centers for Disease Control and Prevention. Meningococcal outbreaks [Internet]. 2019 [cited 2019 Nov 20]. Available from: https://www.cdc.gov/meningococcal/outbreaks/index.html
- Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–723.
- Advisory Committee on Immunization Practices. Summary report, February 27–28, 2019 [Internet]. 2019 Feb 27–28 [cited 2019 Nov 20]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2019-02-508.pdf
- Vuocolo S, Balmer P, Gruber WC, et al. Vaccination strategies for the prevention of meningococcal disease. Hum Vaccin Immunother. 2018;14(5):1203–1215.
- Immunization Action Coalition. State information: meningococcal ACWY state mandates for elementary and secondary schools [Internet]. 2019 [cited 2019 Nov 1]. Available from: https://www.immunize.org/laws/menin_sec.asp
- Immunization Action Coalition. State information: meningococcal ACWY prevention mandates for colleges and universities [Internet]. 2019 [cited 2019 Nov 1]. Available from: https://www.immunize.org/laws/menin.asp